» Articles » PMID: 24726725

Wild Type P53 Reactivation: from Lab Bench to Clinic

Overview
Journal FEBS Lett
Specialty Biochemistry
Date 2014 Apr 15
PMID 24726725
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The p53 tumor suppressor is the most frequently inactivated gene in cancer. Several mouse models have demonstrated that the reconstitution of the p53 function suppresses the growth of established tumors. These facts, taken together, promote the idea of p53 reactivation as a strategy to combat cancer. This review will focus on recent advances in the development of small molecules which restore the function of wild type p53 by blocking its inhibitors Mdm2 and MdmX or their upstream regulators and discuss the impact of different p53 functions for tumor prevention and tumor eradication. Finally, the recent progress in p53 research will be analyzed concerning the role of p53 cofactors and cellular environment in the biological response upon p53 reactivation and how this can be applied in clinic.

Citing Articles

Translating p53-based therapies for cancer into the clinic.

Peuget S, Zhou X, Selivanova G Nat Rev Cancer. 2024; 24(3):192-215.

PMID: 38287107 DOI: 10.1038/s41568-023-00658-3.


The influence of a modified p53 C-terminal peptide by using a tumor-targeting sequence on cellular apoptosis and tumor treatment.

Guo X, Zhang Y, Li Q, Shi F, HuangFu Y, Li J Apoptosis. 2023; 29(5-6):865-881.

PMID: 38145442 DOI: 10.1007/s10495-023-01926-1.


p53 amyloid aggregation in cancer: function, mechanism, and therapy.

Li J, Guo M, Chen L, Chen Z, Fu Y, Chen Y Exp Hematol Oncol. 2022; 11(1):66.

PMID: 36171607 PMC: 9520902. DOI: 10.1186/s40164-022-00317-7.


MiRNA as a Potential Target for Multiple Myeloma Therapy-Current Knowledge and Perspectives.

Szudy-Szczyrek A, Ahern S, Krawczyk J, Szczyrek M, Hus M J Pers Med. 2022; 12(9).

PMID: 36143213 PMC: 9503263. DOI: 10.3390/jpm12091428.


Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications.

Li J, Peng L, Chen Q, Ye Z, Zhao T, Hou S Cancers (Basel). 2022; 14(14).

PMID: 35884437 PMC: 9318555. DOI: 10.3390/cancers14143377.